Bladder cancer

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Friday, September 8, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 8, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations

Retrieved on: 
Tuesday, September 5, 2023
Oncology, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Immortalised cell line, Upjohn, GMP, Amgen, IIT, Medical Affairs Bureau, University, Bureau of Oceans and International Environmental and Scientific Affairs, Blas, University of Maryland, College Park, GU, Record, American Society of Pediatric Hematology/Oncology, Dartmouth–Hitchcock Medical Center, Bladder cancer, Multimedia, Research, Priscilla Chan, Assistant, AbCellera, National Cancer Institute, Urology, Patient, Division, Oslo-Fergene, Hematology, IND, Sanofi, Indian Institutes of Technology, Growth, Merck Serono, SVP, Chemical engineering, Caregiver, Disease, Management, Nursing, Photocure, Seagen, Pfizer

View the full release here: https://www.businesswire.com/news/home/20230905869419/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230905869419/en/
    Ambaw Bellete, President and Chief Operating Officer, CG Oncology (Photo: Business Wire)
    “CG Oncology is at an important stage in our growth, advancing our late-stage clinical pipeline to address unmet medical needs in bladder cancer.
  • Ambaw, Swapnil and Vijay bring decades of experience and proven track records in developing immunotherapy agents from research to commercialization,” said Arthur Kuan, Chief Executive Officer, CG Oncology.
  • Previously, Vijay was the VP, Clinical Development and Medical Affairs and a member of the executive leadership team at AVEO.
  • He was also SVP of Scientific Affairs at FerGene, leading Medical Affairs, Clinical Operations, Regulatory and Clinical Development.

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

Retrieved on: 
Thursday, August 24, 2023
Carcinoma in situ, Biologics license application, Ferring Pharmaceuticals, PAS, NMIBC, Cancer, Bladder cancer, CIS, Research, Urinary bladder, BCG, Papillary tumors of the pineal region, Patient, Ferring, Growth, United, FDA, BLA, SAINT, Pharmaceutical industry, Fine chemical, Nadofaragene firadenovec

Under the terms of the agreement, Royalty Pharma is acquiring a 5.1% percentage royalty on net sales of Adstiladrin in the United States, which will increase to 8.0% upon payment of the manufacturing-related milestone.

Key Points: 
  • Under the terms of the agreement, Royalty Pharma is acquiring a 5.1% percentage royalty on net sales of Adstiladrin in the United States, which will increase to 8.0% upon payment of the manufacturing-related milestone.
  • The royalty is expected to end in the early to mid-2030s.
  • It also highlights its significant potential as a key growth driver for Ferring, and our commitment to Uro-Oncology,” said Jean-Frédéric Paulsen, Executive Chairman of Ferring Pharmaceuticals.
  • “Adstiladrin is the first gene therapy in our diversified royalty portfolio.

Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)

Retrieved on: 
Thursday, August 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Carcinoma in situ, Biologics license application, Ferring Pharmaceuticals, Pharma, PAS, NMIBC, Cancer, Bladder cancer, CIS, Urinary bladder, BCG, Papillary tumors of the pineal region, Patient, Growth, United, FDA, BLA, Pharmaceutical industry, Fine chemical, Nadofaragene firadenovec

Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-vncg) for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment.

Key Points: 
  • Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-vncg) for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment.
  • Under the terms of the agreement, Royalty Pharma is acquiring a 5.1% percentage royalty on net sales of Adstiladrin in the United States, which will increase to 8.0% upon payment of the manufacturing-related milestone.
  • The royalty is expected to end in the early to mid-2030s.
  • It also highlights its significant potential as a key growth driver for Ferring, and our commitment to Uro-Oncology,” said Jean-Frédéric Paulsen, Executive Chairman of Ferring Pharmaceuticals.

NEW STUDY SHOWS UROAMP CAN DETECT BLADDER CANCER NOT FOUND BY CYSTOSCOPY OR URINE CYTOLOGY

Retrieved on: 
Tuesday, August 22, 2023
Carcinoma, DNA, Urine, Genomics, Cancer, AUA, Pathology, Clinical Cancer Research, American Urological Association, Bladder cancer, Harvard Medical School, American Cancer Society, Doctor of Philosophy, Assistant, Genome, MD, Patient, Risk, SAN, Blood, Annual general meeting, Cystoscopy, Diagnosis, Research, Massachusetts General Hospital, FDA, Recurrence, Hematuria, Disease, Dietary supplement, Nursing, Antibiotics, Medical imaging, Urology

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ -- UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can detect bladder cancer or predict its recurrence before clinical signs or symptoms appear, according to a newly published study in the journal Clinical Cancer Research.

Key Points: 
  • In a multi-center case-control study, researchers from leading academic centers and urology practices throughout the United States* compared UroAmp's diagnostic and prognostic performance for bladder cancer to standard-of-care procedures, like cystoscopy, cytology and pathology.
  • UroAmp uses next-generation DNA sequencing to deeply interrogate 60 of the most high-impact urothelial cancer genes for mutations while broadly measuring changes across the whole genome.
  • A comprehensive genomic profile is then generated providing prognostic information about a patient's cancer and predicted responses to genome-targeted drug therapies.
  • The study builds upon recent discoveries from large public research efforts , further defining the most important areas of the genome commonly mutated in bladder cancer.

Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development

Retrieved on: 
Wednesday, August 16, 2023
Translation, Medical Affairs Bureau, University, Berkeley, GU, Bladder cancer, Research, Medicine, Boston University, Tavarua, CDTX, Immunotherapy, Georgetown University, National Cancer Institute, DFC, Cancer, Patient, SAN, Therapy, Nursing, Pharmaceutical industry

SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development. In this position, Dr. Davarpanah will lead the company’s oncology efforts, focusing on the strategy for preclinical, translational, and early clinical development activities to identify and advance drug candidates through human proof-of-concept studies.

Key Points: 
  • In this position, Dr. Davarpanah will lead the company’s oncology efforts, focusing on the strategy for preclinical, translational, and early clinical development activities to identify and advance drug candidates through human proof-of-concept studies.
  • "We welcome Dr. Davarpanah as a key addition to our executive leadership team, where she will lead our oncology clinical development strategy,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics.
  • During that time, part of her work focused on leading the development strategy of immunotherapy combinations in bladder cancer.
  • Dr. Davarpanah received her Doctor of Medicine degree from Boston University, as well as her Juris Doctor degree from the University of California, Berkeley.

Urology Market Segmentation and Projections: Benign Prostatic Hyperplasia, Non-Muscle-Invasive Bladder Cancer, and More Explored - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 16, 2023
Health, Oncology, Maintenance, Prevalence, COVID-19, Consumer, Research, USD, Urology, Investment, R, Bladder cancer, Marketing, Video game, Medical device, Ridesharing, Kidney stone disease

The report provides crucial insights on various aspects of the Global Urology Market, answering questions such as:

Key Points: 
  • The report provides crucial insights on various aspects of the Global Urology Market, answering questions such as:
    What is the market size and forecast of the Global Urology Market?
  • What is the market share of the leading vendors in the Global Urology Market?
  • The report provides a comprehensive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players in the Global Urology Market.
  • The report offers intelligent insights into future technologies, R&D activities, and breakthrough product developments in the urology market.

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September

Retrieved on: 
Monday, August 14, 2023
Abstract, Society, CSO, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, University, Karolinska Institute, Therapy, Maharashtra University of Health Sciences

HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies. Two abstracts have been accepted for presentation at the meeting.

Key Points: 
  • XNK Therapeutics AB today announced that two posters, regarding bladder cancer and acute myeloid leukemia (AML) respectively, will be presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September
    HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies.
  • Two abstracts have been accepted for presentation at the meeting.
  • NK2023 is the 20th annual meeting arranged by the Society of Natural Immunity and takes place in Oslo, Norway, on September 26-29, 2023.
  • The meeting will attract more than 450 participants and is focused entirely on NK cells, with a preceding day entirely focused on the development of NK cell-based immunotherapies.

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September

Retrieved on: 
Monday, August 14, 2023
Abstract, Society, CSO, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, University, Karolinska Institute, Therapy, Maharashtra University of Health Sciences

HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies. Two abstracts have been accepted for presentation at the meeting.

Key Points: 
  • XNK Therapeutics AB today announced that two posters, regarding bladder cancer and acute myeloid leukemia (AML) respectively, will be presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September
    HUDDINGE, Sweden, Aug. 14, 2023 /PRNewswire/ -- XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company's leading natural killer (NK) cells therapies.
  • Two abstracts have been accepted for presentation at the meeting.
  • NK2023 is the 20th annual meeting arranged by the Society of Natural Immunity and takes place in Oslo, Norway, on September 26-29, 2023.
  • The meeting will attract more than 450 participants and is focused entirely on NK cells, with a preceding day entirely focused on the development of NK cell-based immunotherapies.

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Retrieved on: 
Wednesday, August 9, 2023
Research, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Other Science, Senior, SC, NMIBC, Drug, Vanderbilt University Medical Center, Bladder cancer, DRS, Melanoma, Quality, Incidence, CM, Patient, Division, Roivant Sciences, VDC, Growth, Regulatory affairs, SVP, Visual acuity, Fast track (FDA), Safety, Pharmaceutical industry, Nursing, Medical imaging, Medical device, Cryptocurrency

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights.

Key Points: 
  • Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights.
  • The first patient is expected to be dosed in the second half of 2023.
  • Strengthened the clinical leadership team with the following key appointments:
    Dr. Bruce Brown joined Aura as Therapeutic Area Head Urologic Oncology.
  • As of June 30, 2023, Aura had cash and cash equivalents and marketable securities totaling $162.0 million.